Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma
(WorldNews France)

Press Release Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma  Mont Blanc clinical trial to randomize 600+ patients at sites primarily across the U.S.  Adaptive dose selection in Mont Blanc allows the start of the second Phase 3 trial, Denali  NCX 470 will compete in the >$6 billion worldwide glaucoma market1 June 2, 2020 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the initiation of the first Phase 3 clinical trial, named Mont Blanc, evaluating NCX 470 for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, by...